Search
Arcutis Biotherapeutics Inc
ARQTAdd to Watchlist
26.385USD
+0.165+0.63%
Market hours （ET）Quotes delayed by 15 min
3.30BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.63%
5 Days
+0.44%
1 Month
+22.95%
6 Months
-9.14%
Year to Date
-9.14%
1 Year
+88.20%
Key Figures
26.400Open
26.460High
41.52KVolume
LossP/E TTM
23.60P/E Dynamic
--Dividend TTM
0.03%Turnover Ratio
26.220Prev. Close
26.110Low
806.93KTurnover
LossP/E Static
17.40P/B
0.00%Div Yield TTM
-0.59%ROA
31.77052wk High
0.16Volume Ratio
-140.04MNet Profit
125.04MShares
-0.0153EPS TTM
1.53Beta
-1.43%ROE
12.72052wk Low
1.33%Amplitude
90.72%Gross Margin
3.30BMarket Cap
6.90Reward/Risk
3.21%Risk Rate
TradingKey Stock Score of Arcutis Biotherapeutics Inc
Currency: USD Updated: 2026-06-30Key Insights
Arcutis Biotherapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 37 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 34.62.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Arcutis Biotherapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Arcutis Biotherapeutics Inc Highlights
StrengthsRisks
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 530.93% year-on-year.
Undervalued
The company’s latest PE is -1709.26, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 133.41M shares, decreasing 5.32% quarter-over-quarter.
Held by Ron Baron
Star Investor Ron Baron holds 1.19M shares of this stock.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
34.625
Target Price
+29.39%
Upside Space
Arcutis Biotherapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Arcutis Biotherapeutics Inc Info
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.
Ticker SymbolARQT
CompanyArcutis Biotherapeutics Inc
CEOWatanabe (Todd Franklin)
Websitehttps://arcutis.com/
Related Instruments
-1.40%
-1.00%
-2.87%
-1.45%
-2.45%
-2.05%
-0.08%
+2.83%
-0.47%
+0.02%
+0.35%
-1.41%
-1.50%
-2.10%
+0.43%
0.00%
+0.48%
-1.50%
-0.14%
-0.59%Popular Instruments
52389.700
+193.400 (+0.37%)
30042.500
-182.100 (-0.60%)
7493.700
+11.300 (+0.15%)
15373.000
-222.000 (-1.42%)
70236.000
-620.000 (-0.88%)
6286.000
-41.000 (-0.65%)
68.728
-1.193 (-1.71%)
292.200
+2.840 (+0.98%)
195.218
-4.872 (-2.43%)
4095.470
+88.190 (+2.20%)
FAQs
What is the current price of Arcutis Biotherapeutics Inc (ARQT)?
The current price of Arcutis Biotherapeutics Inc (ARQT) is 26.22.
What is the symbol of Arcutis Biotherapeutics Inc?
The ticker symbol of Arcutis Biotherapeutics Inc is ARQT.
What is the 52-week high of Arcutis Biotherapeutics Inc?
The 52-week high of Arcutis Biotherapeutics Inc is 31.77.
What is the 52-week low of Arcutis Biotherapeutics Inc?
The 52-week low of Arcutis Biotherapeutics Inc is 12.72.
What is the market capitalization of Arcutis Biotherapeutics Inc?
The market capitalization of Arcutis Biotherapeutics Inc is 3.28B.
Is Arcutis Biotherapeutics Inc (ARQT) currently rated as Buy, Hold, or Sell?
According to analysts, Arcutis Biotherapeutics Inc (ARQT) has an overall rating of Buy, with a price target of 34.62.
What is the Earnings Per Share (EPS TTM) of Arcutis Biotherapeutics Inc (ARQT)?
The Earnings Per Share (EPS TTM) of Arcutis Biotherapeutics Inc (ARQT) is -0.13.